Alnylam Pharmaceuticals Inc (NAS:ALNY)
$ 265.68 -3.27 (-1.22%) Market Cap: 34.27 Bil Enterprise Value: 33.19 Bil PE Ratio: 0 PB Ratio: 1,062.72 GF Score: 78/100

Alnylam Pharmaceuticals Inc at Jefferies London Healthcare Conference Transcript

Nov 16, 2022 / 02:05PM GMT
Release Date Price: $211.99 (-1.07%)
Maurice Thomas Raycroft
Jefferies LLC, Research Division - Equity Analyst

Hi everyone, Thanks for joining us. My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. It's with great pleasure that I'd like to welcome Yvonne Greenstreet, the CEO of Alnylam. Thanks so much for joining us today, Yvonne.

Yvonne L. Greenstreet
Alnylam Pharmaceuticals, Inc. - CEO & Director

Yes, it's a pleasure to be here. Thank you, and thank you to the audience, too, for joining us today.

Maurice Thomas Raycroft
Jefferies LLC, Research Division - Equity Analyst

And we're doing a fireside chat format. So maybe to start off for those who are new to the Alnylam story, if you can provide a 1-minute intro highlighting your main products and key catalysts.

Yvonne L. Greenstreet
Alnylam Pharmaceuticals, Inc. - CEO & Director

Yes, sure. Well, for those of you that are not familiar with our story, Alnylam is the leading company in RNAi therapeutics. And I think we've

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot